EA199900301A2 - Замещенные трициклические соединения - Google Patents

Замещенные трициклические соединения

Info

Publication number
EA199900301A2
EA199900301A2 EA199900301A EA199900301A EA199900301A2 EA 199900301 A2 EA199900301 A2 EA 199900301A2 EA 199900301 A EA199900301 A EA 199900301A EA 199900301 A EA199900301 A EA 199900301A EA 199900301 A2 EA199900301 A2 EA 199900301A2
Authority
EA
Eurasian Patent Office
Prior art keywords
tricyclic compounds
substituted tricyclic
compounds
substituted
cfla
Prior art date
Application number
EA199900301A
Other languages
English (en)
Other versions
EA002347B1 (ru
EA199900301A3 (ru
Inventor
Бенджамин Алан Андерсон
Николас Джеймс Бах
Жоли Анн Бастиан
Нэнси Кей Харн
Ричард Вальтц Харпер
Гари Алан Хайт
Майкл Дин Кинник
Хо-Шен Лин
Ричард Джеймс Лончарик
Джон МакНейлл МакДжилл III
Эдвард Дэвид Михелик
Джон Майкл мл. Морин
Майкл ЛеРой Филлипс
Майкл Энрико Ричетт
Дэниел Джон Солл
Джейсон Скотт Сойер
Ричард Вальтер Шевитц
Роберт Теодор Василефф
Original Assignee
Эли Лилли Энд Компани
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Эли Лилли Энд Компани filed Critical Эли Лилли Энд Компани
Publication of EA199900301A2 publication Critical patent/EA199900301A2/ru
Publication of EA199900301A3 publication Critical patent/EA199900301A3/ru
Publication of EA002347B1 publication Critical patent/EA002347B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/80—[b, c]- or [b, d]-condensed
    • C07D209/82—Carbazoles; Hydrogenated carbazoles
    • C07D209/88—Carbazoles; Hydrogenated carbazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the ring system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/58—[b]- or [c]-condensed
    • C07D209/70—[b]- or [c]-condensed containing carbocyclic rings other than six-membered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Описан класс новых трициклических соединений, а также применение таких соединений для ингибирования сФЛАопосредованного высвобождения жирных кислот для лечений состояний, таких как септический шок.
EA199900301A 1998-04-17 1999-04-16 Замещенные трициклические соединения EA002347B1 (ru)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US6232898A 1998-04-17 1998-04-17

Publications (3)

Publication Number Publication Date
EA199900301A2 true EA199900301A2 (ru) 1999-10-28
EA199900301A3 EA199900301A3 (ru) 2000-04-24
EA002347B1 EA002347B1 (ru) 2002-04-25

Family

ID=22041763

Family Applications (2)

Application Number Title Priority Date Filing Date
EA199900303A EA002816B1 (ru) 1998-04-17 1999-04-16 Производные карбазола
EA199900301A EA002347B1 (ru) 1998-04-17 1999-04-16 Замещенные трициклические соединения

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EA199900303A EA002816B1 (ru) 1998-04-17 1999-04-16 Производные карбазола

Country Status (30)

Country Link
EP (2) EP0952149B1 (ru)
JP (2) JP4435330B2 (ru)
KR (2) KR100586761B1 (ru)
CN (1) CN1149193C (ru)
AR (2) AR018186A1 (ru)
AT (2) ATE271037T1 (ru)
AU (2) AU753436B2 (ru)
BR (2) BR9902365A (ru)
CA (2) CA2269262A1 (ru)
CO (2) CO5011054A1 (ru)
CZ (2) CZ136999A3 (ru)
DE (2) DE69918590T2 (ru)
DK (1) DK0950657T3 (ru)
DZ (1) DZ2769A1 (ru)
EA (2) EA002816B1 (ru)
ES (2) ES2226286T3 (ru)
HU (2) HUP9901221A3 (ru)
ID (2) ID23287A (ru)
IL (2) IL129483A0 (ru)
NO (2) NO314400B1 (ru)
NZ (3) NZ335251A (ru)
PE (2) PE20000476A1 (ru)
PL (2) PL332566A1 (ru)
PT (1) PT950657E (ru)
SG (2) SG81977A1 (ru)
SI (1) SI0950657T1 (ru)
TR (2) TR199900853A2 (ru)
TW (1) TWI238160B (ru)
YU (2) YU19199A (ru)
ZA (2) ZA992771B (ru)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999009978A1 (en) * 1997-08-28 1999-03-04 Eli Lilly And Company Method for treatment of non-rheumatoid athritis
DZ2769A1 (fr) * 1998-04-17 2003-12-01 Lilly Co Eli Composés tricycliques substitués.
WO2000037022A2 (en) * 1998-12-21 2000-06-29 Eli Lilly And Company Combination therapy for the treatment of sepsis
AU5873400A (en) * 1999-07-19 2001-02-05 Eli Lilly And Company spla2 inhibitors
US6706752B1 (en) 1999-07-19 2004-03-16 Eli Lilly And Company sPLA2 inhibitors
WO2002000257A1 (fr) * 2000-06-29 2002-01-03 Shionogi & Co., Ltd. Remedes a la maladie d'alzheimer
AU2001267824A1 (en) * 2000-06-29 2002-01-08 Shionogi And Co., Ltd. Remedies for cancer
US6967200B2 (en) 2000-06-29 2005-11-22 Shionogi & Co., Ltd. Remedies for cirrhosis
EP1303262A2 (en) * 2000-07-14 2003-04-23 Eli Lilly And Company Use of a spla2 inhibitor for the treatment of sepsis
CA2431028A1 (en) * 2000-12-18 2002-06-27 Ho-Shen Lin Tetracyclic carbazole derivates and their use as spla2 inhibitors
CA2441077A1 (en) 2001-03-28 2002-10-10 Eli Lilly And Company Substituted carbazoles as inhibitors of spla2
AUPS282602A0 (en) 2002-06-07 2002-06-27 Garvan Institute Of Medical Research Method of inhibiting cell proliferation
DE10249055A1 (de) 2002-10-22 2004-05-06 Bayer Cropscience Ag 2-Phenyl-2-substituierte-1,3-diketone
JO3598B1 (ar) 2006-10-10 2020-07-05 Infinity Discovery Inc الاحماض والاسترات البورونية كمثبطات اميد هيدروليز الحامض الدهني
EP1988098A1 (en) * 2007-04-27 2008-11-05 AEterna Zentaris GmbH Novel Tetrahydrocarbazole Derivatives as Ligands of G-protein Coupled Receptors
CA2719721C (en) 2008-03-26 2012-12-18 Daiichi Sankyo Company, Limited Tetrahydroisoquinoline derivative
WO2009126691A1 (en) 2008-04-09 2009-10-15 Infinity Pharmaceuticals, Inc Inhibitors of fatty acid amide hydrolase
WO2010084402A2 (en) * 2009-01-22 2010-07-29 Orchid Research Laboratories Ltd. Heterocyclic compounds as phosphodiesterase inhibitors
AU2010234445A1 (en) 2009-04-07 2011-11-03 Infinity Pharmaceuticals, Inc. Inhibitors of fatty acid amide hydrolase
AU2010234449A1 (en) 2009-04-07 2011-11-03 Infinity Pharmaceuticals, Inc. Inhibitors of fatty acid amide hydrolase
JP2013518886A (ja) 2010-02-03 2013-05-23 インフイニトイ プハルマセウトイカルス インコーポレイテッド 脂肪酸アミドヒドロラーゼ阻害剤
AR088377A1 (es) 2011-10-20 2014-05-28 Siena Biotech Spa Proceso para la preparacion de 6-cloro-2,3,4,9-tetrahidro-1h-carbazol-1-carboxamida y compuestos intermedios de esta
CN102816107B (zh) * 2012-08-20 2015-06-03 东南大学 咔唑衍生物及其制备方法与用途
MX2015006871A (es) 2012-11-30 2015-09-16 Ge Healthcare Ltd Proceso de cristalizacion de derivados de indoles triciclicos.
JP2016501211A (ja) * 2012-11-30 2016-01-18 ジーイー・ヘルスケア・リミテッド 三環性インドールを得るためのハロゲン化亜鉛による環化プロセス
WO2016116527A1 (de) * 2015-01-20 2016-07-28 Cynora Gmbh Organische moleküle, insbesondere zur verwendung in optoelektronischen bauelementen
CN108707104A (zh) * 2018-08-07 2018-10-26 北京恒信卓元科技有限公司 2-氯-1h-咔唑-1,4(9h)-二酮的合成方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3579534A (en) * 1969-05-09 1971-05-18 American Cyanamid Co Tetrahydrocarbazolecarboxylates
US3939177A (en) * 1972-11-22 1976-02-17 Sterling Drug Inc. 4-Aminomethyl-9-benzyl-1,2,3,4-tetrahydrocarbazoles
US3979391A (en) * 1972-11-22 1976-09-07 Sterling Drug Inc. 1,2,3,4-Tetrahydrocarbazoles
PT95692A (pt) * 1989-10-27 1991-09-13 American Home Prod Processo para a preparacao de derivados de acidos indole-,indeno-,piranoindole- e tetra-hidrocarbazole-alcanoicos, ou quais sao uteis como inibidores de pla2 e da lipoxigenase
US5420289A (en) * 1989-10-27 1995-05-30 American Home Products Corporation Substituted indole-, indene-, pyranoindole- and tetrahydrocarbazole-alkanoic acid derivatives as inhibitors of PLA2 and lipoxygenase
JPH06509087A (ja) * 1991-07-05 1994-10-13 メルク　シヤープ　エンド　ドーム　リミテツド 芳香族化合物、それらを含む医薬組成物、及び治療におけるそれらの使用
MY110227A (en) * 1991-08-12 1998-03-31 Ciba Geigy Ag 1-acylpiperindine compounds.
IL109311A0 (en) * 1993-04-16 1994-07-31 Lilly Co Eli 1H-indole-3-acetamide sPla2 inhibitors
IL109309A (en) * 1993-04-16 2000-06-29 Lilly Co Eli 1-H-indole-3-acetic acid hydrazide SPLA2 inhibitors and pharmaceutical compositions containing them
ES2151993T3 (es) * 1995-06-23 2001-01-16 Lilly Co Eli 1,2,3,4-tetrahidro-9h-carbazoles 6-sustituidos y 10h-ciclohepta(7,6-b)indoles 7-sustituidos.
US6160175A (en) * 1995-12-13 2000-12-12 Eli Lilly And Company Naphthyl acetamides as sPLA2 inhibitors
JP2001503055A (ja) * 1996-10-30 2001-03-06 イーライ・リリー・アンド・カンパニー 置換三環化合物群
EP1007056A1 (en) * 1997-09-26 2000-06-14 Eli Lilly And Company Method for the treatment of cystic fibrosis
AU1407399A (en) * 1997-11-14 1999-06-07 Eli Lilly And Company Treatment for alzheimer's disease
DZ2769A1 (fr) * 1998-04-17 2003-12-01 Lilly Co Eli Composés tricycliques substitués.

Also Published As

Publication number Publication date
EP0950657A3 (en) 2001-08-16
DE69918590T2 (de) 2005-07-21
TR199900853A3 (tr) 1999-11-22
SI0950657T1 (en) 2005-02-28
ES2222663T3 (es) 2005-02-01
CN1253948A (zh) 2000-05-24
ES2226286T3 (es) 2005-03-16
PE20000476A1 (es) 2000-06-02
DZ2769A1 (fr) 2003-12-01
HUP9901220A3 (en) 2001-11-28
EP0950657A2 (en) 1999-10-20
BR9901279A (pt) 2000-05-02
TWI238160B (en) 2005-08-21
HUP9901221A3 (en) 2001-11-28
HU9901220D0 (en) 1999-06-28
SG81976A1 (en) 2001-07-24
NZ507564A (en) 2002-10-25
AU2381799A (en) 1999-10-28
CA2269246A1 (en) 1999-10-17
EP0952149B1 (en) 2004-06-09
EP0950657B1 (en) 2004-07-14
NO991821L (no) 1999-10-18
PL332566A1 (en) 1999-10-25
CA2269262A1 (en) 1999-10-17
ID23287A (id) 2000-04-05
EA002347B1 (ru) 2002-04-25
ID23761A (id) 2000-05-11
KR19990083232A (ko) 1999-11-25
TR199900843A2 (xx) 2000-02-21
AR018186A1 (es) 2001-10-31
DE69917833D1 (de) 2004-07-15
AU2381999A (en) 1999-10-28
NO991821D0 (no) 1999-04-16
PL332565A1 (en) 1999-10-25
EA199900303A3 (ru) 2000-04-24
BR9902365A (pt) 2001-04-24
YU19199A (sh) 2002-08-12
DE69918590D1 (de) 2004-08-19
PT950657E (pt) 2004-11-30
KR19990083233A (ko) 1999-11-25
SG81977A1 (en) 2001-07-24
NO991822L (no) 1999-10-18
NZ335253A (en) 2000-11-24
AR018593A1 (es) 2001-11-28
CN1149193C (zh) 2004-05-12
ZA992771B (en) 2002-04-18
CZ137099A3 (cs) 1999-11-17
NZ335251A (en) 2000-11-24
IL129485A0 (en) 2000-02-29
EA002816B1 (ru) 2002-10-31
NO991822D0 (no) 1999-04-16
DE69917833T2 (de) 2005-07-14
EP0952149A2 (en) 1999-10-27
CO5031247A1 (es) 2001-04-27
TR199900853A2 (xx) 1999-11-22
PE20000432A1 (es) 2000-05-23
CO5011054A1 (es) 2001-02-28
ATE271037T1 (de) 2004-07-15
AU753436B2 (en) 2002-10-17
YU18999A (sh) 2002-08-12
AU753547B2 (en) 2002-10-24
EA199900301A3 (ru) 2000-04-24
IL129483A0 (en) 2000-02-29
HU9901221D0 (en) 1999-06-28
KR100586761B1 (ko) 2006-06-08
JP2000026416A (ja) 2000-01-25
ZA992772B (en) 2002-07-16
CA2269246C (en) 2009-08-25
HU9901220A (hu) 2000-04-28
JPH11322713A (ja) 1999-11-24
DK0950657T3 (da) 2004-11-22
NO312240B1 (no) 2002-04-15
NO314400B1 (no) 2003-03-17
CZ136999A3 (cs) 1999-11-17
EA199900303A2 (ru) 1999-10-28
EP0952149A3 (en) 2001-08-16
ATE268756T1 (de) 2004-06-15
HU9901221A (hu) 2000-04-28
JP4435330B2 (ja) 2010-03-17

Similar Documents

Publication Publication Date Title
EA199900301A2 (ru) Замещенные трициклические соединения
ES2179088T3 (es) Inhibidores de flsa2 1h-indol-3-glioxilamida.
EA199900304A2 (ru) Замещенные трициклические соединения
RU94012931A (ru) Гидразиды 1н-индол-3-уксусной кислоты как ингибиторы spla2
ATE246501T1 (de) Pyrrole als spla2 inhibitoren
KR970704695A (ko) 인돌리진 sPLA₂억제제(INDOLIZINE sPLA₂INHIBITORS)
ES2160897T3 (es) Pirazoles como inhibidores de la secretora fosfolipasa a2 humana no pancreatica.
YU19299A (sh) Supstituisani tricikli
ES2159347T3 (es) Naftil-acetamidas como inhibidores de spla2.
ATE234850T1 (de) Phenylglyoxamide als spla2-inhibitoren
ATE326963T1 (de) Indolverbindungen als spla2 inhibitoren
EA200100297A1 (ru) Моногидрат гидробромида элетриптана
PT1206452E (pt) Processo de preparacao de compostos benzoper-hidroisoindole
ATE247119T1 (de) Substituierte pyrroloindole
ATE350367T1 (de) Spla2 inhibitoren
ECSP992928A (es) Compuestos triciclicos sustituidos (caso x-12144)

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM RU